This variation is likely driven by disparities in life expectancy, healthcare access, and the widespread implementation of prostate-specific antigen (PSA) screening, as well as variations in cancer registry reporting practices, all of which contribute to regional differences in prostate cancer incidence and diagnosis. This evidence concerns the gene KLK3 and Familial prostate cancer.